Image

North America Acute Respiratory Distress Syndrome (ARDS) Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jan 2022
  • North America
  • 350 Pages
  • No of Tables: 80
  • No of Figures: 40

North America Acute Respiratory Distress Syndrome (ARDS) Market, By Cause  (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Type (Diagnosis and Treatment), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada and Mexico) Industry Trends and Forecast to 2029.

North America Acute Respiratory Distress Syndrome (ARDS) Market

Market Analysis and Insights: North America Acute Respiratory Distress Syndrome (ARDS) Market

North America acute respiratory distress syndrome (ARDS) market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 10.5% in the forecast period of 2022 to 2029 and is expected to reach USD 7,500.48 million by 2029. Increasing prevalence of COVID-19 act as driver for the acute respiratory distress syndrome (ARDS) market growth.

Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that allows fluid to leak into the lungs. Most people who get ARDS are already at the hospital for trauma or illness like COVID-19. The syndrome usually occurs when fluids build up in the tiny, elastic air sacs called alveoli in lungs. This fluid build-up causes less oxygen reach the bloodstream. This deprives the organs to get enough oxygen for their normal function. People with other illness develops ARDS within few hours to days after the precipitating injury or infection. The risk of death increases with age and depending on severity of illness patients surviving the syndrome becomes hard.  Severe illness or injury which causing damage to the membrane sacs of lungs leads to ARDS. The most common underlying causes for the said diseases includes sepsis, inhalation of harmful substances, severe pneumonia, head, chest or other major injury, coronavirus disease 2019 (COVID-19)  and others.

Increasing prevalence and incidence of acute lung injury, wide range of risk factors for ARDS and acceleration in patient pool of covid-19 with ARDS acts as driver for the acute respiratory distress syndrome (ARDS) market. The other factors which are anticipated to propel the growth of the North America acute respiratory distress syndrome (ARDS) market include the rising rate of air pollution and life style related diseases and Increasing accident rates and trauma causing ARDS.

However, the factors such as the complications associated with treatments, high cost of devices and treatments are hampering the growth of the North America acute respiratory distress syndrome (ARDS) market. On the other hand, the growing geriatric population, rising healthcare expenditure and strategic Initiatives by market players act as an opportunity for the growth of the North America acute respiratory distress syndrome (ARDS) market. The stringent Regulations for approval and multiple challenges faced by ICU nurses is the key market challenge faced in the North America acute respiratory distress syndrome (ARDS) market.

The acute respiratory distress syndrome (ARDS) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the acute respiratory distress syndrome (ARDS) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Acute Respiratory Distress Syndrome (ARDS) Market

Acute Respiratory Distress Syndrome (ARDS) Market Scope and Market Size

The acute respiratory distress syndrome (ARDS) market is segmented on basis of cause, type, route of administration, end users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of cause, the North America acute respiratory distress syndrome (ARDS) market is segmented into coronavirus disease 2019 (COVID-19), sepsis, inhalation of harmful substances, severe pneumonia and others. In 2022, coronavirus disease 2019 (COVID-19) segment is expected to dominate the market as the disease has spread all over the region with huge death rates.
  • On the basis of type, the North America acute respiratory distress syndrome (ARDS) market is segmented into diagnosis and treatment. In 2022, diagnosis segment is expected to dominate the market as people were more aware of the timely diagnosis for proper treatment for deadly disorder.
  • On the basis of route of administration, the North America acute respiratory distress syndrome (ARDS) market is segmented into oral, parenteral and others. The parenteral segment is further segmented into intramuscular and intravenous. In 2022, parenteral segment is expected to dominate the market due to high range of products getting approved by FDA with increasing number of products under pipeline.
  • On the basis of end-users, the North America acute respiratory distress syndrome (ARDS) market is segmented into hospitals, specialty clinics, home healthcare and others. In 2022, hospitals segment is expected to dominate the market due to high technological developments in developed part of country.
  • On the basis of distribution channel, the North America acute respiratory distress syndrome (ARDS) market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2022, direct tender segment is expected to dominate the market as the players are taking strategic initiatives in expanding their distribution channel for worldwide supply.

Acute Respiratory Distress Syndrome (ARDS) Market Country Level Analysis

The acute respiratory distress syndrome (ARDS) market is analyzed and market size information is provided by the country, five notable segments such as cause, type, route of administration, end users and distribution channel as referenced above.

The countries covered in the acute respiratory distress syndrome (ARDS) market report are U.S., Canada and Mexico.

Hospitals segment in the U.S. is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of increasing government and organizational support. The hospitals segment in Canada is second dominating the market owing to increasing cases of chronic respiratory diseases and high adoption of proper diagnosis. Mexico is third leading the growth of the market and hospitals segment is dominating in this country due to increasing number of new hospital infrastructure being opened due to emergence of COVID-19.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to Enhance the Awareness for Acute Respiratory Distress Syndrome (ARDS) Treatment, is Boosting the Market Growth of Acute Respiratory Distress Syndrome (ARDS) Market

The acute respiratory distress syndrome (ARDS) market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.

Competitive Landscape and Acute Respiratory Distress Syndrome (ARDS) Market Share Analysis

Acute respiratory distress syndrome (ARDS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to acute respiratory distress syndrome (ARDS) market.

The major companies which are dealing in the acute respiratory distress syndrome (ARDS) are Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Armstrong Medical, Smiths Medical (part of ICU Medical, Inc.), ResMed, ALung Technologies, Inc., Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., EUROSETS and among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contract and agreement are also initiated by the companies’ worldwide which are also accelerating the acute respiratory distress syndrome (ARDS) market.

For instance,

  • In May 2021, Medtronic announced the launch of SonarMed airway monitoring system. The system utilizes acoustic technology to check for endotracheal tube obstruction. This has helped the company to increase its product portfolio.
  • In July 2020, F. Hoffman-La Roche Ltd announced the launch of SARS-CoV-2 rapid antibody test. The test was launched in partnership with SD Biosenseor, Inc. This has helped the company to increase its product portfolio.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company footprints in the acute respiratory distress syndrome market which also provides the benefit for organization’s profit growth.

Customization Available: North America Acute Respiratory Distress Syndrome (ARDS) Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: PIPELINE ANALYSIS

TABLE 2 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA ORAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA CORONAVIRUS DISEASE 2019 (COVID-19) IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA SEPSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA INHALATION OF HARMFUL SUBSTANCES IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA SEVERE PNEUMONIA IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA HOSPITALS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA SPECIALTY CLINICS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA HOME HEALTHCARE IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA DIRECT TENDER IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA HOSPITAL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA RETAIL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA ONLINE PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 44 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 45 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 46 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 47 U.S. DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 U.S. IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 U.S. TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 52 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 54 U.S. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 55 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 56 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 57 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 58 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 59 CANADA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 CANADA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 CANADA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 66 CANADA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 67 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 68 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 69 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 70 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 71 MEXICO DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 MEXICO IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 MEXICO TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 74 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 78 MEXICO PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 79 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 80 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions